Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 16, Number 9—September 2010

Research

Pediatric Pneumococcal Serotypes in 4 European Countries

Germaine Hanquet1Comments to Author , Esther Kissling, Asuncion Fenoll, Robert C. George, Agnes Lepoutre, Tinne Lernout, David Tarragó, Emmanuelle Varon, and Jan Verhaegen
Author affiliations: Author affiliations: Scientific Institute of Public Health, Brussels, Belgium (G. Hanquet, E. Kissling, T. Lernout); Belgian Knowledge Centre, Brussels (G. Hanquet); Instituto de Salud Carlos III, Madrid, Spain (A. Fenoll, D. Tarragó,); Health Protection Agency, London, UK (R. George); Institut de Veille Sanitaire, Saint Maurice, France (A. Lepoutre); Hôpital Européen G. Pompidou, Paris, France (E. Varon); Katholieke Universiteit Leuven Pneumococcus Reference Laboratory, Leuven, Belgium (J. Verhaegen)

Main Article

Table 2

Serotype-specific adjusted incidence rates of invasive pneumococcal disease in children <5 years of age before and after marketing of PCV7, Spain, Belgium, France, and England and Wales*

Country/serotypes
     Incidence rate†
Incidence rate ratio
(95% CI)
p value
Prevaccine (1999–2002)
Postmarketing (2005–2006)
Spain
PCV7 types 26.8 11.3 0.4 (0.4–0.5) <0.001
Non-PCV7 types 12.5 31.1 2.5 (2.2–2.8) <0.001
1 2.7 8.1 3.0 (2.4– 3.7) <0.001
7F 0.2 3.0 16.9 (8.6–37.7) <0.001
19A
1.9
7.2
3.7 (2.9–4.8)
<0.001
Belgium
PCV7 types 38.7 30.0 0.8 (0.7–0.9) 0.002
Non-PCV7 types 19.7 41.3 2.1 (1.8–2.5) <0.001
1 3.4 9.5 2.8 (1.9– 4.1) <0.001
7F 1.1 5.9 5.3 (2.9–9.8) <0.001
19A
4.4
9.7
2.2 (1.5–3.1)
<0.001
France
PCV7 types 11.9 5.7 0.5 (0.4–0.6) <0.001
Non-PCV7 types 4.9 9.0 1.9 (1.5–2.2) <0.001
1 0.6 1.5 2.7 (1.6–4.7) <0.001
7F 0.3 1.3 4.2 (2.2–8.6) <0.001
19A
1.3
2.4
1.9 (1.3–2.7)
<0.001
England and Wales
PCV7 types 14.6 18.2 1.3 (1.1–1.4) <0.001
Non-PCV7 types 4.7 7.8 1.6 (1.4–1.9) <0.001
1 0.5 1.9 3.8 (2.6–5.8) <0.001
7F 0.4 0.9 2.2 (1.3–3.7) 0.002
19A 0.8 1.0 1.3 (0.8–2.0) 0.271

*PCV7, heptavalent pneumococcal conjugate vaccine; CI, confidence interval. Marketing indicates that the vaccine was marketed and available for use in the country but not introduced in the vaccine schedule free of charge. Vaccine coverage differed by country during this period, ranging from 33% to 48% in Spain, Belgium, and France but <1% in England and Wales. PCV7 types include serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F.
†Cases per 100,000 children <5 years of age. Data for 1999–2002 are annual averages. Prevaccine period is 2001–2002 for France (data not available for previous years).

Main Article

1Current affiliation: Belgian Healthcare Agency, Brussels, Belgium.

TOP